Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy

Fujita, 1994, Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite, J. Antibiot. (Tokyo), 47, 208, 10.7164/antibiotics.47.208 Brinkmann, 2009, FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system, Br. J. Pharmacol., 158, 1173, 10.1111/j.1476-5381.2009.00451.x Schwab, 2007, Finding a way out: lymphocyte egress from lymphoid organs, Nat. Immunol., 8, 1295, 10.1038/ni1545 Foster, 2007, Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis, J. Pharmacol. Exp. Ther., 323, 469, 10.1124/jpet.107.127183 Miron, 2010, Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices, Am. J. Pathol., 176, 2682, 10.2353/ajpath.2010.091234 Choi, 2011, FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation, Proc. Natl. Acad. Sci. U. S. A., 108, 751, 10.1073/pnas.1014154108 Kim, 2011, Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model, FASEB J., 25, 1509, 10.1096/fj.10-173203 Fukushima, 2001, Lysophospholipid receptors, Annu. Rev. Pharmacol. Toxicol., 41, 507, 10.1146/annurev.pharmtox.41.1.507 Gardell, 2006, Emerging medicinal roles for lysophospholipid signaling, Trends Mol. Med., 12, 65, 10.1016/j.molmed.2005.12.001 Spiegel, 2003, Sphingosine-1-phosphate: an enigmatic signalling lipid, Nat. Rev. Mol. Cell Biol., 4, 397, 10.1038/nrm1103 Takabe, 2008, “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets, Pharmacol. Rev., 60, 181, 10.1124/pr.107.07113 Dev, 2008, Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis, Pharmacol. Ther., 117, 77, 10.1016/j.pharmthera.2007.08.005 Budde, 2002, First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients, J. Am. Soc. Nephrol., 13, 1073, 10.1681/ASN.V1341073 Yanagawa, 1998, J. Immunol., 160, 5493, 10.4049/jimmunol.160.11.5493 Brinkmann, 2002, The immune modulator FTY720 targets sphingosine 1-phosphate receptors, J. Biol. Chem., 277, 21453, 10.1074/jbc.C200176200 Mandala, 2002, Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists, Science, 296, 346, 10.1126/science.1070238 Matloubian, 2004, Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1, Nature, 427, 355, 10.1038/nature02284 Mullershausen, 2009, Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors, Nat. Chem. Biol., 5, 428, 10.1038/nchembio.173 Hla, 2011, Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation, Neurology, 76, S3, 10.1212/WNL.0b013e31820d5ec1 Beer, 2000, EDG receptors as a therapeutic target in the nervous system, Ann. N. Y. Acad. Sci., 905, 118, 10.1111/j.1749-6632.2000.tb06544.x Teshima, 1995, FTY720, a Novel Immunosuppressant, Possessing Unique Mechanisms. III. Pharmacological Activities in Several Autoimmune and Inflammatory Models, 5172 Gold, 2006, Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research, Brain, 129, 1953, 10.1093/brain/awl075 Steinman, 2005, Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis, Trends Immunol., 26, 565, 10.1016/j.it.2005.08.014 Stromnes, 2006, Active induction of experimental allergic encephalomyelitis, Nat. Protoc., 1, 1810, 10.1038/nprot.2006.285 Ben-Nun, 1981, The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis, Eur. J. Immunol., 11, 195, 10.1002/eji.1830110307 Aktas, 2007, Neuronal damage in brain inflammation, Arch. Neurol., 64, 185, 10.1001/archneur.64.2.185 Ransohoff, 2006, EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis, Trends Immunol., 27, 167, 10.1016/j.it.2006.02.007 Bartholomaus, 2009, Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions, Nature, 462, 94, 10.1038/nature08478 Greter, 2005, Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis, Nat. Med., 11, 328, 10.1038/nm1197 Aktas, 2005, Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL, Neuron, 46, 421, 10.1016/j.neuron.2005.03.018 Krishnamoorthy, 2009, Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis, Nat. Med., 15, 626, 10.1038/nm.1975 Fujino, 2003, Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment, J. Pharmacol. Exp. Ther., 305, 70, 10.1124/jpet.102.045658 Kataoka, 2005, FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration, Cell. Mol. Immunol., 2, 439 Webb, 2004, Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice, J. Neuroimmunol., 153, 108, 10.1016/j.jneuroim.2004.04.015 Balatoni, 2007, FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis, Brain Res. Bull., 74, 307, 10.1016/j.brainresbull.2007.06.023 Papadopoulos, 2010, FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses, J. Neurosci. Res., 88, 346, 10.1002/jnr.22196 Rausch, 2004, Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging, J. Magn. Reson. Imaging, 20, 16, 10.1002/jmri.20057 Foster, 2009, FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood–brain-barrier damage, Brain Pathol., 19, 254, 10.1111/j.1750-3639.2008.00182.x Zozulya, 2008, The role of regulatory T cells in multiple sclerosis, Nat. Clin. Pract. Neurol., 4, 384, 10.1038/ncpneuro0832 Sawicka, 2005, The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity, J. Immunol., 175, 7973, 10.4049/jimmunol.175.12.7973 Daniel, 2007, FTY720 ameliorates Th1-mediated colitis in mice by directly affecting the functional activity of CD4+CD25+ regulatory T cells, J. Immunol., 178, 2458, 10.4049/jimmunol.178.4.2458 Sehrawat, 2008, Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators, J. Immunol., 180, 7636, 10.4049/jimmunol.180.11.7636 Heng, 2010, Adoptive transfer of FTY720-treated immature BMDCs significantly prolonged cardiac allograft survival, Transpl. Int., 23, 1259, 10.1111/j.1432-2277.2010.01119.x Zhou, 2009, Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro, Clin. Exp. Immunol., 157, 40, 10.1111/j.1365-2249.2009.03942.x Commodaro, 2010, Evaluation of experimental autoimmune uveitis in mice treated with FTY720, Invest. Ophthalmol. Vis. Sci., 51, 2568, 10.1167/iovs.09-4769 Zhang, 2009, Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats, Exp. Neurol., 216, 75, 10.1016/j.expneurol.2008.11.014 Jorns, 2010, Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation, Endocrinology, 151, 3555, 10.1210/en.2010-0202 Wolf, 2009, The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo, J. Immunol., 183, 3751, 10.4049/jimmunol.0901011 Liu, 2009, The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR, Nat. Immunol., 10, 769, 10.1038/ni.1743 Cohen, 2011, Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis, Ann. Neurol., 69, 759, 10.1002/ana.22426 Miron, 2008, Central nervous system-directed effects of FTY720 (fingolimod), J. Neurol. Sci., 274, 13, 10.1016/j.jns.2008.06.031 Miron, 2008, FTY720 modulates human oligodendrocyte progenitor process extension and survival, Ann. Neurol., 63, 61, 10.1002/ana.21227 Van, 2010, Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions, Glia, 58, 1465, 10.1002/glia.21021 Coelho, 2007, The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors, J. Pharmacol. Exp. Ther., 323, 626, 10.1124/jpet.107.123927 Jung, 2007, Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells, Glia, 55, 1656, 10.1002/glia.20576 Miron, 2008, Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod, Am. J. Pathol., 173, 1143, 10.2353/ajpath.2008.080478 Novgorodov, 2007, Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration, FASEB J., 21, 1503, 10.1096/fj.06-7420com Rau, 2011, Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis, Am. J. Pathol., 178, 1770, 10.1016/j.ajpath.2011.01.003 Osinde, 2007, Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors, Neuropharmacology, 52, 1210, 10.1016/j.neuropharm.2006.11.010 Rouach, 2006, S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK, Eur. J. Neurosci., 23, 1453, 10.1111/j.1460-9568.2006.04671.x Sofroniew, 2009, Molecular dissection of reactive astrogliosis and glial scar formation, Trends Neurosci., 32, 638, 10.1016/j.tins.2009.08.002 Kremer, 2009, p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation, Proc. Natl. Acad. Sci. U. S. A., 106, 9087, 10.1073/pnas.0900204106 Prozorovski, 2008, Sirt1 contributes critically to the redox-dependent fate of neural progenitors, Nat. Cell Biol., 10, 385, 10.1038/ncb1700 Mullershausen, 2007, Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors, J. Neurochem., 102, 1151, 10.1111/j.1471-4159.2007.04629.x Pebay, 2001, Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades, Eur. J. Neurosci., 13, 2067, 10.1046/j.0953-816x.2001.01585.x Edsall, 1997, Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation, J. Neurosci., 17, 6952, 10.1523/JNEUROSCI.17-18-06952.1997 Moore, 1999, Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes, Neuroscience, 94, 405, 10.1016/S0306-4522(99)00288-2 Postma, 1996, Sphingosine-1-phosphate rapidly induces Rho-dependent neurite retraction: action through a specific cell surface receptor, EMBO J., 15, 2388, 10.1002/j.1460-2075.1996.tb00595.x Toman, 2004, Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension, J. Cell Biol., 166, 381, 10.1083/jcb.200402016 Harada, 2004, Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells, J. Neurochem., 88, 1026, 10.1046/j.1471-4159.2003.02219.x Kimura, 2007, Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury, Stem Cells, 25, 115, 10.1634/stemcells.2006-0223 Menn, 2006, Origin of oligodendrocytes in the subventricular zone of the adult brain, J. Neurosci., 26, 7907, 10.1523/JNEUROSCI.1299-06.2006 Picard-Riera, 2002, Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice, Proc. Natl. Acad. Sci. U. S. A., 99, 13211, 10.1073/pnas.192314199 Mizugishi, 2005, Essential role for sphingosine kinases in neural and vascular development, Mol. Cell. Biol., 25, 11113, 10.1128/MCB.25.24.11113-11121.2005 Kappos, 2006, Oral fingolimod (FTY720) for relapsing multiple sclerosis, N. Engl. J. Med., 355, 1124, 10.1056/NEJMoa052643 Mehling, 2008, FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis, Neurology, 71, 1261, 10.1212/01.wnl.0000327609.57688.ea Mehling, 2011, Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients, Ann. Neurol., 69, 408, 10.1002/ana.22352 Racke, 2010, Understanding the effects of FTY720 on leukocyte trafficking, Arch. Neurol., 67, 1433, 10.1001/archneurol.2010.299 Johnson, 2010, Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis, Arch. Neurol., 67, 1449, 10.1001/archneurol.2010.312 O'Connor, 2009, Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study, Neurology, 72, 73, 10.1212/01.wnl.0000338569.32367.3d Cohen, 2010, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis, N. Engl. J. Med., 362, 402, 10.1056/NEJMoa0907839 Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N. Engl. J. Med., 362, 387, 10.1056/NEJMoa0909494 Hartung, 2009, Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope, Ann. Neurol., 66, 429, 10.1002/ana.21880 Hartung, 2009, New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab, Lancet Neurol., 8, 28, 10.1016/S1474-4422(08)70281-3 Johnson, 2010, Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients, Clin. Immunol., 137, 15, 10.1016/j.clim.2010.06.005 Leypoldt, 2009, Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report, Neurology, 72, 1022, 10.1212/01.wnl.0000344567.51394.e3 Schwarz, 2010, Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis, Neurology, 74, 2022, 10.1212/WNL.0b013e3181e3972b Kowarik, 2011, Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS, Neurology, 76, 1214, 10.1212/WNL.0b013e3182143564 Schmouder, 2006, FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects, J. Clin. Pharmacol., 46, 895, 10.1177/0091270006289853 Gergely, 2009, Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans, Mult. Scler., 15, S125 Sanna, 2004, Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate, J. Biol. Chem., 279, 13839, 10.1074/jbc.M311743200 Kovarik, 2006, Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function, J. Clin. Pharmacol., 46, 149, 10.1177/0091270005283464 Hohlfeld, 2011, Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy, Neurology, 76, S28, 10.1212/WNL.0b013e31820db40f Mehling, 2010, Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis, Neurology, 75, 403, 10.1212/WNL.0b013e3181ebdd64